Intuitive Surgical: A Tale of Strong Operations and Weak Investor Sentiment

Intuitive Surgical presents investors with a puzzling scenario. The pioneer in robotic-assisted surgery is experiencing remarkable business growth, yet its stock price tells a different story, having entered a pronounced downturn. This divergence between operational success and market performance raises a critical question: what is driving this disconnect, and when might confidence return?

Surging Demand Meets Falling Share Price

From an operational standpoint, Intuitive Surgical’s performance appears robust. Global demand for its da Vinci surgical systems continues to accelerate. The company’s installed base grew to 10,488 units by the end of the second quarter of 2025, representing a 14 percent year-over-year increase. A significant driver is the new flagship model, the da Vinci 5, which has become a major success. Second-quarter placements of this system reached 180, more than double the figure from the same period a year earlier.

This commercial momentum is directly reflected in the company’s financial guidance and results. Management has raised its full-year 2025 procedure growth forecast to a new range of 15.5 to 17 percent. Furthermore, second-quarter revenue saw a substantial 21 percent increase compared to the prior year. These are the kind of fundamental strengths that would typically bolster investor optimism.

The Profitability Squeeze

However, the core concern for the market lies not in top-line growth but in profitability. The company’s guidance for 2025 points to an adjusted gross margin of just 66 to 67 percent, a notable decline from the 69.1 percent achieved in 2024. This compression is attributed to two primary factors. Firstly, tariffs are estimated to negatively impact the margin by approximately a full percentage point. Secondly, the rollout of the more advanced, yet costlier, da Vinci 5 system is putting temporary pressure on profit margins. The combination of rising costs during a period of expansion is a classic red flag for market participants.

Should investors sell immediately? Or is it worth buying Intuitive Surgical?

Shifting Analyst Sentiment and Market Risks

The conflicting signals from strong operations and weaker margins are prompting a more cautious stance among financial analysts. The research firm William Blair recently slightly lowered its earnings estimates for the third quarter of 2025. While the overall consensus rating remains a “Moderate Buy,” these adjustments indicate that the market is increasingly pricing in the challenges to profitability.

Additional headwinds include potential risks from international healthcare budget constraints, which could dampen future system sales in key markets. The stock currently trades significantly below its key moving averages and has lost more than a quarter of its value since the start of the year.

The central dilemma for investors is whether Intuitive Surgical is undergoing a fundamental re-rating or if the current weakness represents a buying opportunity while the market overlooks strong operational data. The resolution likely hinges on the company’s ability to navigate its margin challenges without sacrificing its impressive growth trajectory.